96709 ⎘
Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links; Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE
#2OFF-THE-SHELF CANCER VACCINES
#3PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE
#4PEPTIDE HAVING ACE INHIBITORY ACTIVITY AND COMPOSITION CONTAINING THE SAME
#5FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS
#6RILUZOLE PRODRUGS AND THEIR USE
#7SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS
#8METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES
#9PREPARATION METHOD FOR OXIDIZED GLUTATHIONE AND CRYSTAL FORM AND IMPURITY THEREOF
#10TRANSFECTION COMPLEXES AND METHODS OF USING THE SAME
#11SELECTIVE SMALL MOLECULE AGONISTS AND PARTIAL AGONISTS OF TRK RECEPTORS
#12DEUTERATED COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCERS ASSOCIATED WITH ETBR ACTIVATION
#13PEPTIDES FOR REGULATING GLUCOSE
#14HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY
#15METHOD TO ENHANCE THE EFFICIENCY OF SYSTEMIC AAV GENE DELIVERY TO THE CENTRAL NERVOUS SYSTEM
#16PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE
#17SMALL MOLECULE DRUG CONJUGATES
#18RILUZOLE PRODRUGS AND THEIR USE
#19Riluzole prodrugs and their use
#20GRANZYME B INHIBITOR COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF SKIN BLISTERING AND/OR PEELING
#21SMALL MOLECULE INHIBITORS OF SARS-CoV-2 VIRAL REPLICATION AND USES THEREOF
#22HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS
#23Riluzole prodrugs and their use
#24Peptide macrocycles against
#25LABYRINTHIN-BASED PEPTIDES FOR CANCER IMMUNOTHERAPIES AND USES THEREOF
#26Prodrugs of riluzole and their method of use
#27PEPTIDE-BASED COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE
#28PEPTIDE ACETALS FOR STABILISING ENZYMES
#29Transfection complexes and methods of using the same
#30SITE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS
#31GEMINOID LIPOPEPTIDE COMPOUNDS AND THEIR USES
#32PEPTIDE INHIBITORS OF TIGHT JUNCTION PERMEABILITY
#33METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES
#34METHOD FOR PRODUCING PEPTIDE COMPOUND, PROTECTIVE GROUP-FORMING REAGENT, AND CONDENSED POLYCYCLIC AROMATIC HYDROCARBON COMPOUND
#35FAP-activated proteasome inhibitors for treating solid tumors
#36Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
#37Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
#38Small Molecule Drug Conjugates
#39HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY
#40OFF-THE-SHELF CANCER VACCINES
#41Riluzole prodrugs and their use
#42PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE
#43Riluzole prodrugs and their use
#44Prodrugs of glutamine analogs
#45Hemiasterlin derivatives for conjugation and therapy
#46Toll-like receptor 4 (TLR4) inhibitors and use thereof
#47BIOLOGICALLY ACTIVE C-TERMINAL ARGININE-CONTAINING PEPTIDES
#48SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS
#49Compositions comprising cyclic peptides derived from an A-beta peptide
#50Proteasome inhibitors
#51FAP-activated proteasome inhibitors for treating solid tumors
#52Riluzole prodrugs and their use
#53MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS
#54Pro-pigmenting peptides
#55Peptide inhibitors of tight junction permeability
#56Preparation and use of molecular site targeted and activated kinase inhibitor
#57Hepatitis C virus NS3/4A protease inhibitors
#58Riluzole prodrugs and their use
#59AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS
#60PRODRUG OF AN ICE INHIBITOR
#61GRANZYME B INHIBITOR COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF SKIN BLISTERING AND/OR PEELING
#62Interferon Analogs
#63INSULIN A-CHAIN DERIVED PEPTIDE FRAGMENT AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES OR DIABETIC WOUNDS, CONTAINING THE SAME
#64Inhibitors of hepatitis C virus
#65Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
#66Matriptase inhibitors and uses thereof
#67Prodrugs of glutamine analogs
#68Prodrugs of glutamine analogs
#69Site-specific chemoenzymatic protein modifications
#70Peptide macrocycles against
#71Fine-tune modulators of neuronal excitability for neuropsychiatric disorders
#72MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS
#73Compounds
#74GEMINOID LIPOPEPTIDE COMPOUNDS AND THEIR USES
#75Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
#76Tripeptides having angiotensin converting enzyme inhibitory activity and uses thereof
#77BET protein degraders
#78Anti-inflammatory tripeptides
#79Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
#80Pro-pigmenting peptides
#81PAR2 mimetic peptides and uses thereof
#82FAP-activated proteasome inhibitors for treating solid tumors
#83Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system
#84Inhibitors of hepatitis C virus
#85Peptide macrocycles against Acinetobacter baumannii
#86Transfection complexes and methods of using the same
#87PRODRUG OF AN ICE INHIBITOR
#88Interferon analogs
#89Substituted 6a,7,8,9,10,12-hexahydrobenzo[e]pyrido[1,2-a][1,4]diazepines as anti-proliferative agents
#90Small Molecule Drug Conjugates
#91Methods and reagents for analyzing protein-protein interfaces
#92Methods and reagents for analyzing protein-protein interfaces
#93Prodrugs of glutamine analogs
#94Selective cysteine protease inhibitors and uses thereof
#95MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS
#96Hepatitis C virus inhibitors
#97Cardiovascular Therapeutics
#98Inhibition of gliadin peptides
#99NOVEL INHIBITORS OF MAMMALIAN TIGHT JUNCTION OPENING
#100Dipeptidyl peptidase-IV (DPPIV), inhibitory peptide compound, composition containing the same, and production method for the same
#101Pro-Amb reverse turn restricted bioactive peptide analogues
#102Indoline compounds as granzyme B inhibitors
#103SFRP5-derived peptide fragment and cosmetic composition for skin whitening containing same
#104BIOLOGICALLY ACTIVE C-TERMINAL ARGININE-CONTAINING PEPTIDES
#105Nannocystin process and products
#106Crystalline forms of an antiviral compound
#107Compounds for enzyme inhibition
#108ALDEHYDE CAPTURE LIGATION TECHNOLOGY FOR SYNTHESIS OF AMIDE BONDS
#109Peptide macrocycles against acinetobacter baumannii
#110Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
#111Azaindoline compounds as granzyme B inhibitors
#112Discovery of the first selective C5A receptor 2 (C5L2/C5AR2) ligands
#113Methods and reagents for analyzing protein-protein interfaces
#114INHIBITION OF GLIADIN PEPTIDES
#115Biologically active C-terminal arginine-containing peptides
#116Macrocyclic broad spectrum antibiotics
#117Sfrp5-derived peptide fragment and cosmetic composition for skin whitening containing same
#118Pro-pigmenting peptides
#119Hepatocyte Growth Factor Mimics as Therapeutic Agents
#120Small molecule drug conjugates
#121Myoblast differentiation promoter
#122Tripeptide epoxyketone compound constructed by heterocycle and preparation method and use thereof
#123Prodrug of an ICE inhibitor
#124Covalent granzyme B inhibitors
#125Proline compounds as Granzyme B inhibitors
#126NOVEL ULTRASHORT HYDROPHOBIC PEPTIDES THAT SELF-ASSEMBLE INTO NANOFIBROUS HYDROGELS AND THEIR USES
#127Self-assembling peptides, peptidomimetics and peptidic conjugates as building blocks for biofabrication and printing
#128Inhibitors of hepatitis C virus
#129FAP-activated proteasome inhibitors for treating solid tumors
#130Antibody that specifically binds partially processed or unprocessed neurotoxin polypeptides
#131Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
#132Homo- and heterodimeric SMAC mimetic compounds as apoptosis inducers
#133Peptide domains that bind small molecules of industrial significance
#134Interferon Analogs
#135ASSAY FOR INSULIN-DEGRADING ENZYME (IDE) INHIBITORS
#136Photolabile linker for the solid-phase synthesis of hydrazides and pyranopyrazoles
#137Hemiasterlin derivatives for conjugation and therapy
#138Cell-free protein synthesis method and device using a eukaryotic cell lysate in the presence of a caspase inhibitor and the use of a caspase inhibitor for increasing the yield and/or the stability of the synthesized proteins in such a method
#139Methods and intermediates for preparing macrolactams
#140Anti-inflammatory tripeptides
#141HCV protease inhibitors and uses thereof
#142SITE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS
#143Aminostatin derivatives for the treatment of arthrosis
#144NOVEL INHIBITORS OF MAMMALIAN TIGHT JUNCTION OPENING
#145Crystal forms
#146Dipeptidyl peptidase-IV (DPPIV), inhibitory peptide compound, composition containing the same, and production method for the same
#147Compounds useful as immunomodulators
#148INHIBITORS OF HEPATITIS C VIRUS
#149Indoline compounds as granzyme B inhibitors
#1504-amino-4-oxobutanoyl peptides as inhibitors of viral replication
#151Liquid automatic dish washing detergent compositions
#152Hepatitis C virus inhibitors
#153SMALL MOLECULE MODULATORS OF PCSK9 AND METHODS OF USE THEREOF
#154Amphiphilic linear peptide/peptoid and hydrogel comprising the same
#155Compounds for enzyme inhibition
#156Crystal forms
#157Anti-inflammatory proteins and peptides and methods of preparation and use thereof
#158Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
#159AGENT FOR PREVENTING ARTERIOSCLEROSIS, AGENT FOR SUPPRESSING VASCULAR INTIMAL THICKENING AND AGENT FOR IMPROVING VASCULAR ENDOTHELIAL FUNCTION
#160Prodrug of an ice inhibitor
#161Pro-pigmenting peptides
#162HCV NS3 protease inhibitors
#163Tripeptide rhodamine compound
#164Dipeptidyl peptidase-IV inhibitor
#165Aldehyde capture ligation technology for synthesis of amide bonds
#166INHIBITION OF GLIADIN PEPTIDES
#167Synthesis of telaprevir and boceprevir, or pharmaceutically acceptable salts or solvates as well as intermediate products thereof including β-amino acids prepared via Mukaiyama aldol addition
#168Process for producing self-assembling peptide derivatives
#169HCV protease inhibitors and uses thereof
#170Synthesis of an antiviral compound
#171Crystalline forms of an antiviral compound
#172COMBINATION THERAPY FOR TREATING HCV INFECTION IN AN HCV-HIV COINFECTED PATIENT POPULATION
#173Protease detection
#174DIPEPTIDE AND TRIPEPTIDE COMPOSITIONS AND USES
#175Homo- and heterodimeric SMAC mimetic compounds as apoptosis inducers
#176BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES
#177Compositions containing delta-9-THC-amino acid esters and process of preparation
#178Organogels and emulsions for biological and non-biological applications
#179Modulators of protease activated receptors
#180Macrocyclic compounds for suppressing replication of hepatitis C virus
#181Site-specific chemoenzymatic protein modifications
#182Hepatitis C virus inhibitors
#183Cytotoxic peptides and antibody drug conjugates thereof
#184Organic compounds and their uses
#185IAP BIR domain binding compounds
#186Stabilized subtilisin composition
#1874-amino-4-oxobutanoyl peptides as inhibitors of viral replication
#188DPP-4 inhibitor
#189HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER
#190HCV NS3 protease inhibitors
#191Method of producing peptide
#192ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
#193FAP-activated proteasome inhibitors for treating solid tumors
#194Compositions and methods for inhibiting proteases
#195Methods and intermediates for preparing macrolactams
#196Versatile native chemical ligation technologies
#197Crystal forms of a HCV protease inhibitor
#198Prion protein ligands and methods of use
#199Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof
#200Process and intermediates for preparing macrolactams
#201Macrocyclic cysteine protease inhibitors and compositions thereof
#202Macrocyclic proline derived HCV serine protease inhibitors
#203HCV protease inhibitors
#204Method for synthesis of peptide using a carrier
#205HEPATOCYTE GROWTH FACTOR (HGF) MIMICS AS THERAPEUTIC AGENTS
#206Amphiphilic linear peptidepeptoid and hydrogel comprising the same
#207Hepatocyte growth factor mimics as therapeutic agents
#208Tripeptides Incorporating Deuterium as Inhibitors of Hepatitis C Virus
#209Compounds for enzyme inhibition
#210Hepatocyte growth factor mimics as therapeutic agents
#211Antiviral compounds
#212Compounds for enzyme inhibition
#213Selective cysteine protease inhibitors and uses thereof
#214Macrocyclic compounds and methods for their production
#215Compounds for enzyme inhibition
#216Neuroprotective and neurorestorative methods and compositions
#217Inhibitors of hepatitis C virus
#218Compositions for the treatment or prophylaxis of viral infections
#219HCV protease inhibitors and uses thereof
#220Compounds for enzyme inhibition
#221Lissencephaly therapeutic agent
#222Bioactive peptide
#223Process for making HCV protease inhibitors
#224ISOLATION OF MESENCHYMAL STEM CELLS
#225COMPOUNDS FOR ENZYME INHIBITION
#226Tripeptides Incorporating Deuterium as Inhibitors of Hepatitis C Virus
#227Peptides that inhibit angiotensin converting enzyme and peptides with antioxidant activity purified from ovotransferrin and methods of producing and using the same
#228Inhibitors of the trypsin-like site of the proteasome and methods of use thereof
#229Cardiovascular therapeutics
#230IAP BIR domain binding compounds
#231Interferon analogs
#232Antiviral compounds
#233Compounds for enzyme inhibition
#234Compounds for enzyme inhibition
#235Compounds for enzyme inhibition
#236Peptidomimetic sulfamide compounds and antiviral uses thereof
#237C-Met receptor regulation by angiotensin IV (AT4) receptor ligands
#238Amphiphilic linear peptide/peptoid and hydrogel comprising the same
#239Peptidomimetic sulfamide compounds and antiviral uses thereof
#240HCV protease inhibitors and uses thereof
#241Hepatitis C virus inhibitors
#242Optimal hydolysis conditions of soy protein to produce peptides with lipolysis-stimulating activity and their sequencing and use thereof
#243OPTIMIZED METHOD FOR OBTAINING ACE ACTIVITY INHIBITORY PEPTIDES FROM WHEY, ACE INHIBITORY PEPTIDES AND FOOD COMPRISING THEM
#244Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use
#245SERINE HYDROLASE FORMULATION
#246Hemiasterlin derivatives and uses thereof in the treatment of cancer
#247Peptides binding to the dimer interface of thymidylate synthase for the treatment of cancer
#248Immunoconjugates, compositions for making them, and methods of making and use
#249Peptidomimetic protease inhibitors
#250Process for preparing peptide products for promoting cholecystokinin secretion and use of the peptide products
#251Hepatitis C Inhibitor Compounds
#252Native chemical ligation at serine and threonine sites
#253Compound and methods for its production
#254Processes for preparing protease inhibitors of hepatitis C virus
#255Organic compounds and their uses
#256Insulin analogues
#257Antiviral compounds
#258HCV protease inhibitors and uses thereof
#259Biologically active peptides and their new uses
#260ANTI-INFLAMMATORY AGENT FOR ORAL APPLICATION, AND ANTI-INFLAMMATORY PEPTIDE FOR ORAL APPLICATION
#261Tripeptide boronic acid or boronic ester, preparative method and use thereof
#262PROCESS FOR THE PURIFICATION OF HUMAN GROWTH HORMONE POLYPEPTIDES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS
#263SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION
#264NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION
#265Compounds for enzyme inhibition
#266Macrocyclic proline derived HCV serine protease inhibitors
#267Peptidomimetic protease inhibitors
#268Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
#269PEPTIDE AVAILABILITY
#270AGENT FOR PREVENTING ARTERIOSCLEROSIS, AGENT FOR SUPPRESSING VASCULAR INTIMAL THICKENING AND AGENT FOR IMPROVING VASCULAR ENDOTHELIAL FUNCTION
#271Hepatitis C Inhibitor Compounds
#272VEGFR-1/NRP-1 TARGETING PEPTIDES
#273Neuroprotective and neurorestorative method and compositions
#274Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases
#275G-TYPE PEPTIDES AND OTHER AGENTS TO AMELIORATE ATHEROSCLEROSIS AND OTHER PATHOLOGIES
#276Means and methods for manufacturing highly pure neurotoxin
#277ANTIOXIDANT AGENT
#278Synthetic protease substrates, assay methods using such substrates and kits for practicing the assay
#279Peptidic compounds
#280N-terminally modified tetrapeptide derivatives having a C-terminal arginine mimetic
#281Hepatitis C virus inhibitors
#282MACROLACTONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF CANCER
#283Boronic ester and acid compounds, synthesis and uses
#284Prodrug of an ICE inhibitor
#285Methods of treating cachexia with macrocyclic modulators of the ghrelin receptor
#286ORGANIC COMPOUNDS
#287Inhibition of gliadin peptides
#288FUSION PROTEINS COMPRISING DP-178 AND OTHER VIRAL FUSION INHIBITOR PEPTIDES USEFUL FOR TREATING AIDS
#289VASODILATOR
#290Peptides having an ACE inhibiting effect
#291Compounds and compositions as channel activating protease inhibitors
#292Spatially-defined macrocyclic compounds useful for drug discovery
#293Michael systems as transglutaminase inhibitors
#294Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors
#295Polyheterocyclic compounds highly potent as HCV inhibitors
#296Biologically active C-terminal arginine-containing peptides
#297IAP BIR DOMAIN BINDING COMPOUNDS
#298Hepatitis C inhibitor compounds
#299Angiotensin converting enzyme inhibitory peptide
#300Lactobacillus helveticus strains for producing hypotensive peptides